VASSALLO, C.; CANALI, B.; FIORENTINO, F.; MORELLI, P.; RIPOLI, S.; FIORAVANTI, L. Brentuximab vedotin + AVD in cHL: cost impact on adverse events, toxicity, second malignancies, end-of-life and subsequent lines of therapy in Italy. AboutOpen, [S. l.], v. 10, n. 1, p. 103–109, 2023. DOI: 10.33393/ao.2023.2609. Disponível em: https://journals.aboutscience.eu/index.php/aboutopen/article/view/2609. Acesso em: 3 jul. 2024.